HOUSTON, November 5 /CNW/ - Regenetech, Inc., the tissue regeneration
technology company which has built upon NASA licensed technology, today
announces that it has signed a Mexican, country-exclusive license for its
cellXpansion(TM) technology with Regenevita, a new Mexican company.
The exclusive agreement with the newly formed Regenevita will allow
Regenetech's cellXpansion(TM) technology to be made available for clinical
applications in Mexico. Under the terms of the exclusive agreement, Regenevita
will use Regenetech's technology to expand (multiply) human progenitor cells
from blood for use in research and development activities with the ultimate
objective of commercializing the stem cell expansion process for the benefit
of patients in Mexico. Financial terms of the agreement were not disclosed at
Carlos Morett, CEO of Regenevita, commented: "Regenevita's goal is to
become a leader in Mexico in the tissue regeneration area. We are delighted to
begin working with Regenetech and their strong cellXpansion(TM) technology
position in this area. We believe we can enable the widespread use in Mexico
of tissue regeneration therapy, revolutionary medical treatment that benefits
all people, with cellXpansion technology."
David Bonner, CEO of Regenetech, added: "We are optimistic that this
agreement will lead to increased, rapid innovations in the regenerative
therapy field, expedite human clinical studies, and ultimately, lead to
clinical use. We look forward to working closely with Regenevita to progress
the technology, in addition to increasing our activities in Mexico."
For further information:
For further information: Regenetech, Inc. Timmie Wang, 713-838-5277